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Endothelial pro-inflammatory activation plays a pivotal role in atherosclerosis, and many pro-
inflammatory and atherogenic signals converge upon mechanistic target of rapamycin (mTOR). 
Inhibitors of mTOR complex 1 (mTORC1) reduced atherosclerosis in preclinical studies, but side 
effects including insulin resistance and dyslipidemia limit their clinical use in this context. Therefore, 
we investigated PRAS40, a cell type-specific endogenous modulator of mTORC1, as alternative 
target. Indeed, we previously found PRAS40 gene therapy to improve metabolic profile; however, 
its function in endothelial cells and its role in atherosclerosis remain unknown. Here we show that 
PRAS40 negatively regulates endothelial mTORC1 and pro-inflammatory signaling. Knockdown of 
PRAS40 in endothelial cells promoted TNFα-induced mTORC1 signaling, proliferation, upregulation 
of inflammatory markers and monocyte recruitment. In contrast, PRAS40-overexpression 
blocked mTORC1 and all measures of pro-inflammatory signaling. These effects were mimicked by 
pharmacological mTORC1-inhibition with torin1. In an in vivo model of atherogenic remodeling, mice 
with induced endothelium-specific PRAS40 deficiency showed enhanced endothelial pro-inflammatory 
activation as well as increased neointimal hyperplasia and atherosclerotic lesion formation. These 
data indicate that PRAS40 suppresses atherosclerosis via inhibition of endothelial mTORC1-mediated 
pro-inflammatory signaling. In conjunction with its favourable effects on metabolic homeostasis, this 
renders PRAS40 a potential target for the treatment of atherosclerosis.
Atherosclerosis is an inflammatory disorder of large and medium-sized arteries that causes myocardial infarction 
and stroke, which are leading causes of morbidity and mortality worldwide1. Endothelial cell (EC) function and 
pro-inflammatory activation play a pivotal role at all stages of atherosclerosis, from initiation to plaque rupture 
and atherothrombotic complication2.
Intracellularly, a large number of atherogenic stimuli, like signals from growth factors, overnutrition, hyper-
glycemia and other stressors are integrated by the mechanistic target of rapamycin (mTOR)3–5. mTOR exists in 
2 distinct complexes, mTORC1 and mTORC2, and its role as central regulator of cell growth and proliferation is 
well-established3. A growing body of evidence from preclinical studies demonstrates that genetic or pharmaco-
logical inhibition of mTORC1 suppresses atherosclerosis6–15 and promotes longevity in mice16–18. However, sys-
temic mTORC1-inhibition in patients by rapamycin derivatives (rapalogs) is limited by adverse effects, of which 
hyperglycemia, insulin resistance and dyslipidemia are particularly troubling in the context of atherosclerosis19,20. 
1Department of Cardiology, Angiology, and Pneumology, University Hospital Heidelberg, University of Heidelberg, 
Heidelberg, Germany. 2Charité – University Medicine Berlin, Department of Cardiology and Angiology, Charité 
Campus Mitte, Berlin, Germany. 3DZHK (German Centre for Cardiovascular Research), partner site Heidelberg/
Mannheim, Heidelberg, Germany. 4DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, 
Germany. 5These authors contributed equally: Kevin Sun Zhang and Johannes Schecker. 6These authors jointly 
supervised this work: Mirko Völkers and Till F. Althoff. *email: mirko.voelkers@med.uni-heidelberg.de; till.althoff@
charite.de
open
2Scientific RepoRtS |         (2019) 9:16787  | https://doi.org/10.1038/s41598-019-53098-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
Treatment-induced dyslipidemia may also explain why the net effect of pharmacological mTORC1-inhibition on 
cardiovascular risk in renal or liver transplantation patients was only neutral21,22.
Against this background, targeting of cell type-specific endogenous modulators of mTORC1 signaling like 
Proline-rich AKT substrate 40 kDa (PRAS40) may be a promising alternative. PRAS40 was identified as a com-
ponent of the mTORC1 complex that negatively regulates mTORC1 signaling in a complex manner, which is only 
incompletely understood and, according to genetic evidence from Drosophila, highly cell type-dependent. This 
cell type-specific impact of PRAS40 on mTORC1 signaling may confer a therapeutic profile that is distinct from 
conventional mTORC1-inhibitors - possibly without the adverse effects that limit their clinical use in the context 
of atherosclerosis23. Indeed, we have previously demonstrated that PRAS40 gene therapy with adenoviral vectors 
improves hepatic insulin sensitivity and reduces systemic hyperglycemia and dyslipidemia in obese mice. Thus, 
in contrast to rapamycin and its derivatives, mTORC1-inhibition with PRAS40 appears to improve metabolic 
profile24.
However, the function of PRAS40 in distinct mammalian cell types, particularly endothelial cells, remains to 
be defined, and its role in vascular disease processes like atherosclerosis has not been investigated. Here we use in 
vitro loss-of-function and gain-of-function studies, as well as a conditional endothelial-specific PRAS40-knockout 
mouse model to investigate the endothelial function of PRAS40 in the context of atherosclerosis.
Results
PRAS40 Inhibits mTORC1 in Endothelial Cells. PRAS40 function has been shown to be highly cell 
type-dependent. Thus, in order to test its impact on mTORC1 signaling in endothelial cells, cultured human 
umbilical vein endothelial cells (HUVECs) were transfected with siRNA directed against PRAS40 or with scram-
ble siRNA. mTORC1-mediated signaling was markedly enhanced by PRAS40 knockdown, as evidenced by 
increased phosphorylation of its downstream targets S6Kinase (S6K) and eukaryotic translation initiation factor 
4E-binding protein 1 (4EBP1), respectively (Fig. 1a,b). In contrast, PRAS40 overexpression using recombinant 
Figure 1. PRAS40 inhibits mTORC1 signaling in endothelial cells. (a,b) Representative immunoblot for 
indicated proteins after siRNA-mediated knockdown of PRAS40 in HUVECs and statistical analysis for 
indicated proteins based on analysis of 3 individual biological replicates. Data represent mean ± SEM; 
***P < 0.001; ****P < 0.0001 (two-tailed student’s t-test). (c,d) Representative immunoblot for indicated 
proteins after adenoviral overexpression of PRAS40 in HUVECs and statistical analysis for indicated proteins 
based on analysis of 3 individual biological replicates. Data represent mean ± SEM; *P < 0.05; ****P < 0.0001 
(two-tailed student’s t-test).
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adenoviruses inhibited mTORC1-mediated signaling in HUVECs (Fig. 1c,d). Thus, loss- and gain-of-function 
studies indicate a negative regulation of mTORC1 by PRAS40 in endothelial cells.
PRAS40 Negatively Regulates Endothelial Pro-Inflammatoy Signaling
mTORC1 has been shown to regulate pro-inflammatory signaling as well as expression of atherogenic chemok-
ines and leukocyte adhesion molecules like ICAM-125–27. In order to elucidate the role of PRAS40 in the context 
of endothelial atherogenic signaling, we treated HUVECs with the pro-inflammatory cytokine tumor necrosis 
factor alpha (TNFα), which resulted in increased mTORC1 signaling and upregulation of ICAM-1 (Fig. 2a,b). 
Interestingly, siRNA-mediated knockdown of PRAS40 significantly augmented this TNFα-induced mTORC1 
activation and upregulation of ICAM-1. Of note, PRAS40 knockdown also promoted TNFα-induced upregula-
tion of other atherogenic molecules like VCAM-1 and CCL2, as determined by qRT-PCR (Fig. 2c). As specified 
by the given name, PRAS40 contains two proline-enriched stretches at the amino-terminus and an AKT consen-
sus phosphorylation site (RXRXXS/T) located at Thr246. Phosphorylated PRAS40 dissociates from mTORC1 in 
response to growth factors, insulin, glucose and different nutrients and thereby releases the inhibitory function 
of PRAS40 on mTORC1. However, TNFα did not significantly induce phosphorylation of PRAS40 at threo-
nine 256, suggesting that alternative mechanisms are involved in TNFα-induced activation of mTORC1. Still, 
siRNA-mediated knockdown of PRAS40 significantly augmented this TNFα-induced mTORC1 activation and 
upregulation of ICAM-1. In contrast, PRAS40 overexpression completely blocked TNFα-induced activation of 
mTORC1 and attenuated upregulation of the atherogenic leukocyte adhesion molecules ICAM-1 and VCAM-1 
(Fig. 3). As previously published, PRAS40 specifically inhibited mTORC1 as determined by decreased phospho-
rylation of the canonical downstream target S6K, whereas phosphorylation of the mTORC2 downstream target 
AKT was not altered by PRAS40 overexpression.
PRAS40 Attenuates Monocyte Recruitment by Endothelial Cells
In order to define the functional consequence of this negative regulation of mTORC1 activity and 
pro-inflammatory signaling by PRAS40, we tested its effect on monocyte recruitment to endothelial cells in a 
THP-1 monocyte adhesion assay. Consistent with the PRAS40-mediated suppression of leukocyte adhesion 

































































































































































































































































































































Figure 2. PRAS40 knockdown promotes pro-inflammatory signaling in endothelial cells. (a) Representative 
immunoblot for indicated proteins after siRNA-mediated knockdown of PRAS40 in HUVECs and treatment 
with TNFα (2,5 ng/ml). (b) Statistical analysis for indicated proteins based on analysis of 3 individual biological 
replicates. Data represent mean ± SEM; *P < 0.05; ***P < 0.001; ****P < 0.0001 (ANOVA followed by 
Bonferroni’s post-hoc comparisons). (c) Quantitative RT-PCR analysis for indicated transcripts after siRNA-
mediated knockdown of PRAS40 in HUVECs and treatment with TNFα (2,5 ng/ml) based on analysis of 3 
individual biological replicates. Data represent mean ± SEM; *P < 0.05; ***P < 0.001; ****P < 0.0001 (ANOVA 
followed by Bonferroni’s post-hoc comparisons).
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THP-1 monocytes (Fig. 4a). In contrast, PRAS40 overexpression markedly reduced THP-1 monocyte adhesion 
to TNFα-stimulated endothelial cells (Fig. 4b).
PRAS40 Regulates Endothelial Proliferation and Apoptosis
As increased cell turnover is a hallmark of pro-inflammatory endothelial activation in the context of atheroscle-
rosis, we investigated the impact of PRAS40 on endothelial proliferation. Consistent with the pro-inflammatory 
effects outlined above, knockdown of PRAS40 strongly promoted mitogenic effects of VEGF stimulation. 
In contrast, PRAS40 overexpression substantially reduced endothelial proliferation in response to VEGF 
(Supplementary Fig. S1).
Atherosclerosis-related increases in endothelial cell turnover are usually accompanied by enhanced apoptosis, 
and indeed, we also observed increased apoptosis rates upon stimulation with TNFα. PRAS40 overexpression 
strongly enhanced this effect, whereas apoptosis rates were markedly reduced by PRAS40-knockdown, indicating 
an anti-apoptotic effect of mTORC1 signaling in this context (Supplementary Fig. S2).
Pharmacological mTORC1-Inhibition Mimicks the Effects of PRAS40 Overexpression
If PRAS40 indeed exerted its anti-atherogenic effects via negative regulation of mTORC1-mediated signaling, 
the effects of PRAS40 overexpression should be mimicked by pharmacological inhibition of mTORC1. Thus, we 
repeated key loss-of-function experiments using the novel mTOR-inhibitor torin1. mTORC1-mediated signal-
ing, as reflected by phosphorylation of S6K and ribosomal S6 protein (RibS6), was completed blocked by torin1 
Figure 3. PRAS40 overexpression attenuates pro-inflammatory signaling in endothelial cells. (a) Representative 
immunoblot for indicated proteins after adenoviral overexpression of PRAS40 in HUVECs and treatment with 
TNFα (2,5 ng/ml) for indicated timepoints. (b) Statistical analysis for indicated proteins based on analysis of 3 
individual biological replicates. Data represent mean ± SEM; ***P < 0.001. (c) Quantitative RT-PCR analysis 
for indicated transcripts after adenoviral overexpression of PRAS40 in HUVECs and treatment with TNFα 
(2,5 ng/ml) for 8 h based on analysis of 3 individual biological replicates. Data represent mean ± SEM; *P < 0.05; 
**P < 0.01; ****P < 0.0001 (ANOVA followed by Bonferroni’s post-hoc comparisons).
Figure 4. Endothelial PRAS40 regulates TNFα-induced monocyte adhesion. (a) Statistical analysis of fold 
changes in adhesion of mononcytes on HUVECs and representative images of monocyte adhesion after 
staining with Calcein AM after siRNA-mediated PRAS40 knockdown after treatment with TNFα. Data 
represent mean ± SEM; ****P < 0.0001. (b) Statistical analysis of fold changes in adhesion of mononcytes on 
HUVEC after adenoviral overexpression of PRAS40 after treatment with TNFα. Data represent mean ± SEM; 
****P < 0.0001 (ANOVA followed by Bonferroni’s post-hoc comparisons).
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(Fig. 5a,b). Of note, similar to PRAS40 overexpression, torin1-treatment suppressed endothelial upregulation 
of the leukocyte adhesion molecule ICAM-1 and monocyte adhesion to endothelial cells in response to TNFα 
(Fig. 5c,d). In addition, torin1 promoted endothelial apoptosis comparable to the pro-apoptotic effect of PRAS40 
overexpression (Fig. 5e).
Endothelial-Specific PRAS40 Deficiency Promotes Pro-Inflammatoy Signaling and 
Atherogenic Remodeling in vivo
Taken together, the in vitro-studies depicted above, indicate that PRAS40 inhibits atherogenic signaling and 
pro-inflammatory activation of endothelial cells by negative regulation of mTORC1. In order to validate these 
findings in vivo and to test their functional relevance in the context of atherosclerosis, we created a novel trans-
genic mouse line with conditional endothelial-specific PRAS40 deficiency, based on cre/loxP-mediated mutagen-
esis (EC-PRAS40-KO). In this respect we created mice with two loxP-flanked PRAS40-allels, and crossed them 
with mice harbouring a tamoxifen-inducible cre-recombinase under control of the endothelial-specific vascular 
endothelial cadherin (Cdh5)-promotor. Endothelium-specific PRAS40-deficiency was confirmed by immunos-
taining of carotid artery cross sections (Supplementary Fig. S3).
EC-PRAS40-KO mice and Cre-negative littermates were exposed to a model for disturbed blood flow 
and atherogenic vascular remodeling based on partial carotid ligation and western diet: Six weeks after 
tamoxifen-induced recombination and initiation of a western diet, all distal branches of the left common carotid 
artery were ligated, except for the superior thyroid artery, to establish disturbed but continuous blood flow as 
described by us previously (Fig. 6a)28. In combination with sustained western diet, this disturbed blood flow 
results in pro-inflammatory endothelial activation and atherogenic vascular remodeling in terms of neointimal 
hyperplasia and immune cell infiltration within four weeks29. Even though not observed consistently, initial ath-
erosclerotic lesions with isolated foam cells and intracellular lipid accumulation can also develop.
Figure 5. Pharmacological mTORC1-inhibition mimicks effects of PRAS40 overexpression in endothelial cells. 
(a) Representative immunoblot for indicated proteins after pharmacological mTORC1-inhibition with torin1 
upon induction with indicated TNFα concentrations and timepoints. (b,c) Statistical analysis for indicated 
proteins based on analysis of 2 individual biological replicates. Data represent mean ± SEM; **P < 0.01; 
***P < 0.001; ****P < 0.0001 (ANOVA followed by Bonferroni’s post-hoc comparisons). (c) Statistical analysis 
of fold changes in adhesion of mononcytes on HUVECs upon induction with TNFα and after treatment with 
torin1. Data represent mean ± SEM; ****P < 0.0001 (ANOVA followed by Bonferroni’s post-hoc comparisons). 
(e) Analysis of apoptotic HUVECs measured by flow-cytometry (annexin positive cells) after torin1 treatment 
and induction with TNFα (2,5 ng/ml) for 24 h based on the analysis of 3 individual biological replicates. Data 
represent mean ± SEM; **P < 0.01; ****P ≤ 0.0001 (ANOVA followed by Bonferroni’s post-hoc comparisons).
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In line with our in vitro-data indicating an anti-atherogenic function of PRAS40, four weeks after partial 
carotid ligation, atherogenic remodeling and lesion development was strongly enhanced in EC-PRAS40-KO 
mice compared to littermate controls (Fig. 6b,c). Consistent with the concept of PRAS40-mediated inhibition 
of mTORC1-dependent pro-inflammatory signaling, deduced from our in vitro data, endothelial expression 
Figure 6. Endothelial-specific PRAS40 deficiency promotes atherogenic remodeling in vivo. (a) Schematic 
diagram of the partial carotid ligation. Arrows indicate direction of blood flow. Red dotted lines represent cross 
sections for quantitative analyses at indicated predefined distances from the proximal end of the vessel. ECA, 
external carotid artery; ICA, internal carotid artery; STA, superior thyroid artery; OA, occipital artery (b) Mice 
with tamoxifen-induced endothelium-specific PRAS40 deficiency (EC-PRAS40-KO) and tamoxifen-treated 
Cre-negative littermates (WT controls) were continuously exposed to western diet for a total of 10 weeks. Four 
weeks after partial ligation, left common carotid arteries as well as sham-operated right common carotid arteries 
were harvested for further analyses. Shown are representative carotid cross sections at five predefined distances 
from the proximal end of the carotid artery (0 µm, 1000 µm, 2000 µm, 3000 µm, 4000 µm) stained with elastic 
stain. Scale bars in black 100 µm. (c) Mean intimal cross sectional areas (including plaque and neointima) 
were quantified at each predefined distance (based on analysis of 4 different animals per genotype). Shown 
are absolute plaque areas as well as plaque areas in relation to the contralateral sham operated vessel size (area 
enclosed by external elastic lamina). Data represent mean ± SEM; *P < 0.05; **P < 0.01; ***P < 0.001 (two-
tailed student’s t-test).
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of the leukocyte adhesion molecules ICAM-1 and VCAM-1 was markedly enhanced in EC-PRAS40-KO mice 
(Fig. 7a,b). In line with this increased expression of cell adhesion molecules, macrophages were more abundant 
in intimal lesions of EC-PRAS40-KO mice than in littermate controls (Fig. 7c).
Discussion
mTORC1-mediated signaling is activated under atherogenic conditions or in the context of atherosclerosis, and 
inhibition of mTORC1 has been demonstrated to reduce atherosclerotic plaque development through pleiotropic 
effects in a large number of preclinical studies6–15. Moreover, mTORC1-inhibitors like rapamycin or its derivatives 
are known to promote longevity in mice16–18. However, the systemic use of mTORC1-inhibitors in patients is 
limited by adverse effects, of which hyperglycemia, insulin resistance and dyslipidemia are particularly troubling 
in the context of atherosclerosis20. In fact, the significant treatment-induced dyslipidemia may also explain why, 
despite the promising preclinical data, mTORC1-inhibitors had only a neutral net effect on cardiovascular risk 
in renal or liver transplantation patients21,22. In that respect it is noteworthy, that the above-mentioned preclin-
ical studies were largely based on genetic atherosclerosis models resulting in excessive hypercholesterolemia. 
Figure 7. Endothelial-specific PRAS40 deficiency promotes pro-inflammatory signaling in vivo. (a,b) Shown 
are representative carotid cross section stained with DAPI (blue) and antibodies against the cell adhesion 
molecules ICAM-1 and VCAM-1, respectively (red). Scale bars in white 100 µm. Quantifications display 
percentage of endothelial cells defined by histomorphological features that stained positive for ICAM-1 and 
VCAM-1, respectively (based on analysis of 3 predefined sections each, from 4 different animals per genotype). 
(c) Shown are representative carotid cross section stained with an antibody against the macrophage marker 
CD68. Quantifications display the CD68-positive percentage of the intimal cross-sectional area (comprising 
plaque and neointima) based on analysis of 3 sections each, from 4 different animals per genotype. Data 
represent mean ± SEM; *P < 0.05; **P < 0.01 (two-tailed student’s t-test).
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Under these conditions moderate increases in cholesterol levels elicited by mTORC1-inhibition may not come 
into effect.
In this study, we investigated the endogenous mTORC1-modulator PRAS40 as a potential target for the treat-
ment of atherosclerosis. Due to its highly cell type-specific impact on mTORC1 signaling, PRAS40-mediated 
inhibition of mTORC1 may offer a distinct therapeutic profile compared to conventional mTORC1-inhibitors 
- possibly with less adverse effects. Indeed, while rapamycin and its derivatives detrimentally affect lipid and 
glucose homeostasis20, we have previously demonstrated that PRAS40 gene therapy with adenoviral vectors 
improves hepatic insulin sensitivity and reduces systemic hyperglycemia and hyperlipidemia in obese mice24.
However, the specific function of PRAS40 in endothelial cells and a potential role in atherosclerosis have not 
been investigated so far. The in vitro gain-of-function- and loss-of-function-studies presented here, show that 
PRAS40 negatively regulates mTORC1 in endothelial cells, at the same time attenuating endothelial inflamma-
tory activation and monocyte recruitment in response to atherogenic stimuli. These findings are consistent with 
a number of previous reports demonstrating mTORC1-dependent pro-inflammatory signaling in various cell 
types26,27,30. Moreover, systemic mTORC1-inhibition by rapamycin was consistently shown to reduce chemok-
ine expression and monocyte recruitment in experimental atherosclerosis6–8,12,15. Even though mTORC1 func-
tion in this respect has not been specifically defined in endothelial cells, individual reports have suggested an 
mTORC1-dependent endothelial regulation of atherogenic molecules like VCAM-1 or endothelin-131. The pre-
cise mechanisms of mTORC1-mediated pro-inflammatory signaling remain to be elucidated. However, recently 
a non-canonical pathway for the regulation of chemokine expression through mTORC1-mediated dephospho-
rylation of transcription factor forkhead box K1 (FOXK1) has been identified30.
Pro-inflammatory endothelial activation and endothelial monocyte recruitment are critical events in ath-
erosclerotic lesion development. In line with our in vitro findings, endothelial-specific PRAS40-deletion in 
mice resulted in strongly increased atherogenic remodeling and lesion formation in our murine model of par-
tial carotid ligation and western diet. These observations are consistent with numerous reports demonstrating 
anti-atherosclerotic effects of pharmacological mTORC1-inhibition in mice. However, it has to be considered 
that, unlike our murine disease model eliciting only atherogenic remodeling and initial atherosclerotic lesions, 
these studies investigated more advanced stages of atherosclerosis in atheroprone mouse strains lacking the LDL 
receptor or the apolipoprotein E. While these genetic mouse models may better mimic the complete picture of 
human atherosclerosis, the lifelong defect in lipid homeostasis resulting in excessive hypercholesterolemia might 
also be a confounding factor29. Indeed, findings from previous studies suggest that mTORC1-inhibition is less 
effective in late stages of atherosclerosis and that potential effects are obscured by the excessive hypercholester-
olemia in genetic atherosclerosis models7.
Consistent with the anti-inflammatory effects of PRAS40 overexpression in our in vitro experiments and the 
above-mentioned studies on pharmacological mTORC1-inhibition, endothelial expression of the leukocyte adhe-
sion molecules ICAM-1 and VCAM-1 was markedly enhanced in EC-PRAS40-KO mice and coincided with 
higher numbers of immune cells in the respective intimal lesions. These data suggest that PRAS40 exerts its 
atheroprotective function, at least partially, through the suppression of endothelial pro-inflammatory activa-
tion. However, besides its anti-inflammatory effects, we also found PRAS40 to inhibit endothelial proliferation, 
which is in line with well-established effects of mTORC1 signaling on cell cycle-control in various cell types3. 
These anti-mitogenic effects of PRAS40 might contribute to its atheroprotective function, too, and suppression of 
endothelial proliferation has even been proposed to prevent plaque destabilization11.
While the anti-inflammatory and anti-proliferative effects of PRAS40 can be readily reconciled with its athero-
protective function in endothelial cells, the positive regulation of apoptotic signaling may appear conflictive with 
this concept. First of all, our observations of PRAS40-mediated pro-apoptotic effects are in line with a large body 
of evidence demonstrating that mTORC1 is capable of regulating apoptosis through multiple downstream targets 
including apoptosis-regulatory proteins such as p53, Bad and Bcl-2, in a cell type- and context-dependent man-
ner32. Interestingly, both pro- and anti-apoptotic effects of mTORC1 have been reported in endothelial cells33,34. 
The fact that atheroprone vascular regions are characterized by increased endothelial proliferation and apoptosis 
rates may indeed be suggestive of a mechanistic link between endothelial cell turnover and the susceptibility to 
atherosclerotic plaque development. However the role of endothelial apoptosis in atherosclerotic lesion develop-
ment is probably more complex and only incompletely understood35.
After all, the atheroprotective effects of PRAS40 may be pleiotropic, and the relative contributions of its 
anti-inflammatory, anti-proliferative and pro-apoptotic effects in endothelial cells cannot be precisely defined. 
Moreover, we cannot resolve, whether the atheroprotective effects of PRAS40 are indeed exerted via inhibition of 
mTORC1 signaling. However, the fact that the effects of PRAS40 overexpression were mimicked by pharmaco-
logical mTORC1-inhibition is suggestive of such causality.
Thus, based on our studies, we hypothesize that PRAS40 suppresses development of atherosclerosis, at least in 
part, via inhibition of mTORC1-mediated pro-inflammatory signaling in endothelial cells. In conjunction with 
its favourable effects on metabolic homeostasis, the overall therapeutic profile of PRAS40-treatment appears to 
be beneficial, compared to conventional mTORC1-inhibitors, the systemic use of which is limited by off-target 
effects including hyperglycemia, insulin resistance and dyslipidemia. Taken together, PRAS40 may qualify as a 
potential therapeutic target for the treatment of atherosclerosis.
Materials and Methods
Reagents. Rapamycin, diluted and stored in DMSO, was purchased from Santa Cruz Biotechnology 
(sc-3504B). Torin 1, diluted and stored in DMSO, was from Cayman Chemical Company (Iten#10997). TNFα, 
diluted and stored in PBS, was bought from PeproTech (35-01A, LOT No. 121054-1). Protease and phosphatase 
inhibitors were purchased from Roche. β-Mercaptoethanol and DMSO were purchased from Sigma-Aldrich, 
Tween 20 detergent from Carl Roth.
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Cell culture. PBS and RPMI 1640 medium were purchased from Sigma-Aldrich, FBS from Merck Milipore. 
Penicillin, streptomycin & L-glutamine (100x) (PSG), MEM Non-Essential Amino Acids Solution (100x), 
Trypsin/EDTA solution, HEPES buffering agent were from Life Technologies.
Human umbilical vein endothelial cells (HUVECs) were purchased from Lonza and used as a model of 
endothelial cell function. HUVECs were cultivated in Endothelial Cell Growth Medium-2 (EGM-2) (Lonza) 
containing the Endothelial Basal Medium-2 (Lonza), 2% FBS and other growth factors included in the kit by 
Lonza. HUVECs were cultivated and normally used for experiments at passage 5–6. HUVECs were cultivated to 
a maximal confluency of 70–90%. Then a subculturing process was performed, or they were plated into 6-well 
plates for experiments. For reseeding, the cells were washed with PBS and detached using trypsin/EDTA solution 
at 0.025%. For experiments, the endothelial cells, frozen in cryo vials at passage 4, were thawed, cultivated and 
re-plated in 6-well plates at 80,000–120,000 cells per well in EBM-2 medium supplemented with 10% FBS. After 
24 hours, the medium was changed to EBM-2 with 5% FBS to conduct transfection, infection or direct exper-
iments. For cryopreservation, special media was mixed consisting of 80% EGM-2, 10% DMSO and 10% FBS.
The THP-1 monocytes kindly provided by AG Leuschner (University Hospital Heidelberg) belong to a cell line 
derived from an acute monocytic leukemia patient. These suspension cells were cultivated in a medium mixture 
consisting of RPMI 1640 culture medium, 10% FBS, 10 mM HEPES buffering agent, 50 µM β-Mercaptoethanol 
and supplemented with non-essential amino acids and an antibiotic solution of penicillin (100IE/ml), streptomy-
cin (100 µg/ml) and L-glutamine (292 µg/ml) (PSG). A concentration of 300,000–800,000 cells/ml was allowed 
before subculturing was conducted. To verify cell number, medium color was checked daily and cell number was 
determined periodically using a counting chamber. The medium for cryopreservation consisted of 76.5% RPMI 
1640, 18.5% FBS and 5% DMSO supplemented with PSG.
Western blotting. HUVECs were washed with ice-cold PBS and lysed by a protein lysis buffer (20 mM Tris, 
150 mM NaCl, 1% Triton X-100, 0.1% SDS, protease and phosphatase inhibitor). To determine the protein con-
centration, the DC Protein Assay Kit kit (Bio-Rad), based on the Lowry method, was used according to the man-
ufacturer’s instructions. If necessary, the protein samples were frozen at −20 °C before further processing. After 
isolation and the concentration assay, the loading samples were prepared to have a desired protein mass, which 
ranged between 10–15 µg; the rest of the loading sample consisted of Laemmli Sample Buffer (Bio-Rad) supple-
mented with 10% β-Mercaptoethanol and the protein lysis buffer. The loading samples were heated for 5 min-
utes at 95 °C to ensure denaturation. The lysates were resolved using SDS-gels (Bio-Rad #3450118, #3450123) in 
an electrophoresis chamber (Bio-Rad). Afterwards, the proteins were blotted onto a PVDF membrane (Merck 
Millipore). For the immunostaining process, membranes were washed with Tris-buffered saline with Tween 20 
(TBST) and blocked at room temperature for at least 1 hour using I-Block (Life Technologies) dissolved in TBST. 
PVDF membranes were then incubated at 4 °C overnight with the respective primary antibodies diluted in block-
ing reagent and TBST buffer. The proteins targeted by the primary antibodies used were used in the following 
dilutions:
•	 Intercellular adhesion molecule 1 – ICAM-1, 1:25 000; Santa Cruz Biotechnology (sc8439)
•	 Phospho-p70 S6 Kinase (Thr389) – pS6K1, 1:1000; Cell Signaling Technology (#9205)
•	 Proline-rich Akt substrate of 40 kDa – PRAS40, 1:10 000–1:5000; Cell Signaling Technology (#2691)
•	 Phospho-Proline-rich Akt substrate of 40 kDa (Thr246) – pPRAS40, 1:10000–1:5000
•	 Phospho-Akt (Ser473) – pAkt, 1:1000; Cell Signaling Technology (#9271)
•	 Phospho-S6 Ribosomal Protein (Ser235/236) – pRPS6, 1:5000; Cell Signaling Technology (#2211)
•	 Phospho-4EBP1 (S65) – p4EBP1, 1:5000; Cell Signaling Technology (#9451)
•	 α-Tubulin –1:20 000, Cell Signaling Technology (#2144S)
The detection of the proteins was performed using horseradish peroxidase conjugated secondary antibodies, 
Western Lightning Plus-ECL (Perkin Elmer) and CL-XPosure Films (Thermo Fisher Scientific). Utilizing an open 
source image processing software called Fiji, based on ImageJ, the width and the intensity of each band was deter-
mined as a numerical value. The bands of the protein α-Tubulin served as control.
RNA interference. siRNA dependent RNA interference was utilized in silencing the AKT1S1 gene encod-
ing the protein PRAS40. The siRNAs used were purchased from Thermo Fisher Scientific: Negative Control 
siRNA (Silencer Negative Control No. 2 siRNA – #AM4613) and AKT1S1-targeting siRNA (siRNA ID s38945, 
#4392420). The transfection of the siRNAs was performed using the reagent lipofectamine 2000 (Thermo Fisher 
Scientific) according to the following protocol based on the manufacturer’s instructions. For each well
•	 a dilution of siRNA in 125 µl of EBM-2 resulting in an siRNA concentration of 500 nM was performed.
•	 2,5 µl of the transfection reagent was diluted in 125 µl of EBM-2
•	 both reagents were mixed and incubated for 5 minutes
•	 the two mixtures were combined and incubated for 20 minutes
The medium of the cells to be transfected was changed to EBM-2 supplemented with 5% FBS and the prepared 
siRNA complexes were added to each well. This resulted in a final siRNA concentration of 50 nM and a well vol-
ume of 1,25 ml. The cells were exposed to the transfecting medium for 24 hours.
Adenoviral overexpression of PRAS40. Both viruses PRAS40 Wildtype-Adenovirus and 
Control-Adenovirus were generated using the Gateway cloning system36. Normally stored frozen in viral storage 
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buffer (20 nM Tris/HCL, 25 mM NaCl, 2,5% Glycerol, pH adjusted to 8.0 at 22 °C), the viral particles were added 
to the EBM-2 medium with 5% FBS to the desired multiplicity of infection (MOI, number infectious particles per 
cell). The cells were exposed to the viral medium for 24 hours.
Adhesion assay. For the PRAS40 modulation experiments, HUVECs were either transfected with siRNA 
or infected by adenovirus as described above. The day following the transfection or infection, the cells were 
harvested from the 6-well plates and seeded in 96-well plates with a concentration of 50,000 cells and 100 μl 
of EBM-2 supplemented with 10% FBS. For the torin experiments, HUVECs were cultivated parallelly. After 
reseeding, the cells were given 48 hours to reattach and form a complete monolayer. HUVECs were stimulated 
with TNFα, diluted in PBS, at a final concentration of 2,5 ng/ml, torin 1 was used at a concentration of 150 nM for 
3 hours. The THP-1 monocytes were stained and prepared using eBioscience Calcein AM Viability Dye (Thermo 
Fisher Scientific), a cell permeant dye staining metabolically active and live cells, according to the Vybrant Cell 
Adhesion Assay Kit’s manual (Thermo Fisher Scientific, #V13181). The stained THP-1 monocytes were added to 
the HUVEC wells at a number of 500 000/well for adhesion and the non-adhering cells were removed by wash-
ing. Utilizing a plate reader, possessing a FITC filter set, the fluorescence of each well was measured at 9 different 
locations after excitation. The mean of each well was used for further data processing.
Apoptosis. Apoptosis was induced by treating the HUVECs with TNFα at 120 ng/ml for 24 hours in EBM-2 
supplemented with 5% FBS. Simultaneously to the addition of TNFα, for the mTOR inhibitor experiments rapa-
mycin and torin 1 were added. After 24 hours treatment was complete and a flow-cytometry (BD FACSVerse) 
dependent assay using the Dead Cell Apoptosis Kit with Annexin V FITC and PI (Thermo Fisher Scientific, 
#V13242) was performed.
Proliferation. For siRNA-mediated knockdown or adenoviral overexpression of PRAS40, HUVECs were first 
cultivated, transfected and infected as described above. Then the cells were harvested and from the 6-well plate 
and reseeded in special imaging 96-well plates (Corning) at desired concentration of approximately 1000 cells per 
well. On day 0, the cells were then given approximately 4 hours to attach to the plate after reseeding to the 96-well 
plates. During the attachment phase, the cells were given medium containing 10% FBS to facilitate the process. 
Afterwards, the initial count was performed using the CyQuant Direct Cell Proliferation Assay Kit. (Thermo 
Fisher Scientific, # C35011). For the counting process itself, pictures were automatically taken, processed and 
counted digitally using  the In Cell Analyzer 2200 and its software. This allowed cell count determination in abso-
lute numbers. For the comparison of cell proliferation over the time course of 3 days, cells were cultivated in 5% 
FBS EBM-2 and either stimulated with VEGF (kindly provided by AG Hassel (University Hospital Heidelberg) 
at a concentration of 50 ng/ml. Medium change including the re-addition of VEGF was performed on day 2 
(48 hours after seeding) of each trial. Measurement of cell count was performed every 24 hours after initial cell 
number determination.
Genetic mouse model. To study PRAS40 in vivo, a novel PRAS40 knockout mouse line was created with 
tamoxifen-inducible endothelial-specific PRAS40 deficiency. An embryonic stem cell clone (EPD0156_2_
A05-European Conditional Mouse Mutagenesis Program) was used to generate mice with loxP-flanked 
PRAS40 allels. Endothelial-specific knockout mice were generated by crossing floxed PRAS40 mice with 
Cdh5(PAC)-CreERT2 mice37. Cre+/−;Pras40fl/fl mice were considered knockout animals (EC-PRAS40-KO), 
whereas Cre-negative littermates were considered wildtype controls.
Mouse model of atherogenic remodeling. From six weeks of age, mice were on continuous western diet 
(Ssniff® TD88137, 0,3% cholesterol) for a total of 10 weeks. At 7 weeks of age Cre recombinase was activated in 
EC-PRAS40-KO mice by intraperitoneal injections of tamoxifen (Sigma, T5648, 1 mg/animal/day on five consec-
utive days). Cre-negative littermate control mice underwent the same procedure.
At 12 weeks of age partial carotid ligation was performed as described by us before28. Briefly, mice were anaes-
thetized by intraperitoneal injection of ketamine (120 mg/kg, Pfizer, Germany) and xylazine (16 mg/kg, Bayer; 
Germany) and placed on a heated surgical pad. After hair removal a midline cervical incision was made and the 
distal branches of the left common carotid artery were exposed. Three of the four branches (external carotid 
artery, internal carotid artery and occipital artery) were then ligated distal to the superior thyroid artery branch 
off, which was left open as an outflow (see schematic diagram in Fig. 6a). 6.0 silk sutures (Serag-Wiessner) were 
used for ligations; the skin was sutured with absorbable 6.0 silk suture (CatGut, Germany). After surgery, animals 
were monitored in a chamber on a heating pad until recovery. Western diet was continued until harvesting of 
carotid arteries 4 weeks after partial carotid ligation.
All animal experiments were approved by the animal ethics committee of the federal state of Berlin 
(Tierversuchskommission des Landes Berlin, Germany) and were performed accordingly under adherence to the 
effective guidelines and the German Protection of Animals Act.
Histology and immunohistochemistry. For histology, vessels were perfused and fixed in 4% PFA 
overnight. Vessels were then rehydrated using increasing concentrations of ethanol and embedded in paraffin. 
Paraffin-embedded arteries were cut in 5-μm serial cross sections mounted on slides.
For morphometric analyses, slides were rehydrated and stained using a Modified Verhoeff Van Gieson Elastic 
Stain Kit (Sigma Aldrich HT25) according to the manufacturer’s instructions. In partially ligated left common 
carotid arteries, cross sections from five predefined distances (0 μm, 1000 μm, 2000 μm, 3000 μm and 4000 
μm, respectively) from the proximal end of the carotid artery were analysed (see schematic diagram in Fig. 6a). 
Photoshop CS5 extended software (Adobe) was used to measure circumferences of internal elastic lamina, 
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external elastic lamina, and lumen, as well as medial, intimal, and luminal cross-sectional areas as described by 
us previously38. For relative analyses plaque areas were quantified in relation to the cross-sectional area of the 
sham-operated contralateral carotid as determined by the area enclosed by the external elastic lamina.
For immunohistochemistry, paraffin sections were rehydrated, and subsequently boiled for 3 minutes in cit-
rate buffer (pH = 6) in a microwave oven for epitope retrieval. Epitopes were then blocked in PBS supplemented 
with 5% normal goat serum and 1% BSA for 30 minutes. Slides were incubated with primary antibodies (1:200 
dilution in blocking buffer) at 4 °C overnight. Primary antibodies were then detected with a biotinylated second-
ary antibody to rabbit IgG followed by incubation with avidin–biotin complex (AK-5000, Vector Laboratories) 
according to manufacturer’s instructions. Staining was then visualized using VectorRed-Kit (SK-5100, Vector 
Laboratories) following the manufacturer’s instructions. Finally, slides were mounted using DAPI-containing 
aqueous mounting medium (H-1200, Vector Labotatories).
Antibodies. Anti-VCAM1: ab134047 (Abcam), anti-ICAM1: ab119871 (Abcam), anti-CD68: ab125212 
(Abcam), anti-rabbit IgG: BA-1000 (Vector Laboratories), anti rat-IgG: BA-9401 (Vector Laboratories).
For quantifitative analyses, the percentage of positively stained endothelial cells (ICAM-1- and VCAM-
1-stainings) or the percentage of positively stained intimal area (CD68 staining) was calculated. Of note, endothe-
lial cells were defined based on characteristic histomorphological features (cells with thin elongated nuclei 
constituting the luminal lining of the vessel). A minimum of three cross sections from the proximal, medial and 
distal part of the vessel were analysed and a vessel mean calculated.
Microscopy. Microscopic images were captured using the Keyence HS all-in-one BZ 9000 microscope. For 
fluorescence images, the CFI Plan Apo λ 40x lens was used. The images have a resolution of 1360 × 1024 pixels, 
while the scaling is 3,75 pixels/µm. Capture time was 1/12 s for DAPI and 1/10 s for VectorRed. Colors are dis-
played as pseudocolors using blue for fluorescence in the DAPI channel and red for Fluorescence in the VectorRed 
channel. The used fluorophores have the following excitation/emission wavelengths: DAPI: 360 nm/460 nm; 
VectorRed: 365–560 nm/ > 560 nm. Images were captured using the following filter sets: DAPI 340/360 nm 
Excitation - 450/460 Emission; VectorRed: 513/556 Excitation – 570/613 Emission.
For images of elastica and CD68 stainings, the CFI Plan Apo λ 20x lens was used. These images have a resolu-
tion of 4080 × 3072 pixels, while the scaling is 5,63 pixels/µm. Capture time was 1/30 s, bit-depth was 24.
Statistics. For statistical analysis, PRISM 6 software by GraphPad Software was utilized. Comparisons in 
experiments of more than two groups were performed with one-way ANOVA without matching or pairing with 
multiple comparisons being performed using preselected groups of interest. In the diagrams, the values presented 
are the arithmetic means of the group with the error bars indicating the standard error of the mean (SEM). If a 
comparison was performed between two groups unpaired t-test was utilized to determine significant difference.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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